@yomommasay So tired of explaining this lol. Read the explanation for sales at bottom. This is an automatic administrative action it happens to almost every executive who gets stock compensation
$SLS will be a huge win
The last patient has already enrolled for 19 months but the 80 events still not happen. The mOS of the GPS arm would be more than 20 months
@TenPennyStocks REGAL trial is Phase 3
The trial is 'event-driven' (80 deaths) and the delays suggest patients are living longer than expected (Bullish).
They just hired the guy who launched Venetoclax to handle commercial strategy.
$2.5B might actually be conservative if REGAL hits."
@TenPennyStocks There presenting the p2 at ash conference this sunday. BUT THERE P3 results for a separate drug gps is being reported by eoy its not a p2 company. They could have an fda approval esrly next year with rotr program. The p3 drug is a platform drug also.